HomeAbout

TL;DR CNBC


FDA approves Merck vaccine designed to protect adults from bacteria that can cause pneumonia, serious infections - TL;DR CNBC

FDA approves Merck vaccine designed to protect adults from bacteria that can cause pneumonia, serious infections

Publishing timestamp: 2024-06-17 19:02:51


Summary

The FDA approved Merck's new vaccine, Capvaxive, designed to protect adults from pneumococcus bacteria that can cause pneumonia. Analysts see this as a key growth driver for Merck as it prepares for losses from its cancer drug Keytruda. The vaccine aims to provide broader protection than others on the market and could potentially capture a majority of the market share among adults.


Sentiment: POSITIVE

Tickers: PFESAN-FRMRKGSK-GBGSKPCVX

Keywords: pfizer incbiotech and pharmaceuticalsbusiness newsbiotechnologysciencevaxcyte incgsk plcmerck & co incbreaking newshealth care industrysanofi sapharmaceuticalsbusiness

Source: https://www.cnbc.com/2024/06/17/fda-approves-merck-pneumococcal-disease-vaccine-designed-for-adults.html


Developed by Leo Phan